Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar 13 for Pneumococcal Prevention in Multiple Myeloma
NCT03619252Phase 4Completed
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Start
- Jul 2018
- Primary completion
- Jan 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection, Pneumococcal pneumonia (PP), febrile neutropenia (FN), sponsored by Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infectionPneumococcal pneumonia (PP)febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT03619252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619252.